Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian CancerShannon N. Westin, Gordon B. Mills, Xiaoyan Ma et al.|Clinical Cancer Research|2021Cited by 76
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancerEmily Hinchcliff, Amir A. Jazaeri, Anne Knisely et al.|Cancer|2023Cited by 18
Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survivalDavid M. Gershenson, Charlotte C. Sun, Lauren Cobb et al.|Gynecologic Oncology|2022Cited by 16
Phase 1b dose expansion and translational analyses of olaparib in combination with the oral AKT inhibitor capivasertib in recurrent endometrial, triple negative breast, and ovarian, primary peritoneal, or fallopian tube cancerShannon N. Westin, Gordon B. Mills, Marilyne Labrie et al.|medRxiv|2021Cited by 11